| 國立臺灣大學 |
2000 |
Incidence of Exit-Site Infection with Various Exchange Systems in Continuous Ambulatory Peritoneal Dialysis
|
黃政文; 洪冠予; 嚴崇仁; 蔡敦仁; HUANG, JENQ-WEN; HUNG, KUAN-YU; YEN, CHUNG-JEN; TSAI, TUN-JEN |
| 國立臺灣大學 |
2013 |
Incidence of first onset alcohol use disorder: a 16-year follow-up in the Taiwanese aborigines
|
Lee, Chau-Shoun; Liao, Shu-Fen; Liu, I-Chao; Lee, Wen-Chung; Cheng, Andrew T. A.; 李文宗 |
| 臺大學術典藏 |
2018-09-10T09:40:59Z |
Incidence of first onset alcohol use disorder: A 16-year follow-up in the Taiwanese aborigines
|
Lee, Chau-Shoun;Liao, Shu-Fen;Liu, I-Chao;Lee, Wen-Chung;Cheng, Andrew T. A.; Lee, C.-S. and Liao, S.-F. and Liu, I.-C. and Lee, W.-C. and Cheng, A.T.A.; 李文宗; WEN-CHUNG LEE; Lee, Chau-Shoun; Liao, Shu-Fen; Liu, I-Chao; Lee, Wen-Chung; Cheng, Andrew T. A. |
| 臺大學術典藏 |
2020-11-19T08:19:32Z |
Incidence of first onset alcohol use disorder: A 16-year follow-up in the Taiwanese aborigines
|
Lee C.-S.;Liao S.-F.;Liu I.-C.;Wen-Chung Lee;Cheng A.T.A.; Lee C.-S.; Liao S.-F.; Liu I.-C.; WEN-CHUNG LEE; Cheng A.T.A. |
| 國立臺灣大學 |
1997 |
Incidence of first onset alcoholism among Taiwanese aborigines
|
CHEN, WEI J.; CHENG, ANDREW T. A. |
| 國立臺灣大學 |
1997-11 |
Incidence of first onset alcoholism among Taiwanese aborigines
|
Chen, W.J.; Cheng, A.T.A. |
| 臺大學術典藏 |
2022-05-05T05:16:37Z |
Incidence of first onset alcoholism among Taiwanese aborigines
|
WEI J. CHEN; Cheng A.T.A. |
| 國立臺灣大學 |
1997 |
INCIDENCE OF FIRST ONSET ALCOHOLISM AMONG TAIWANESE ABORIGINES.
|
CHEN, WEI-JANE; CHENG, TAI-ANN; 陳為堅; 鄭泰安 |
| 臺大學術典藏 |
2018-09-10T06:40:11Z |
Incidence of first onset alcoholism among Taiwanese aborigines.
|
W J Chen; A T Cheng; WEI J. CHEN |
| 國立臺灣大學 |
1983 |
Incidence of Hepatitis Among Students at an Uiwersity in Taiwan
|
涂醒哲; Beaskey, R. Palmer; Hwang, Lu-Yu; Lin, Chia-Chin; Ko, Yuan-Chin; Twu, Shiing-Jer; Beaskey, R. Palmer; Hwang, Lu-Yu; Lin, Chia-Chin; Ko, Yuan-Chin |
| 臺大學術典藏 |
2020-05-26T09:26:19Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non?�small-cell lung cancer patients
|
Yao Z.-H;Liao W.-Y;Ho C.-C;Chen K.-Y;Shih J.-Y;Chen J.-S;Lin Z.-Z;Lin C.-C;Chih-Hsin Yang;Yu C.-J.; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Lin C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-03-30T08:50:43Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yang J.C.-H.; Yu C.-J.; Lin C.-C.; Shih J.-Y.; JIN-SHING CHEN; Lin Z.-Z.; Chen K.-Y.; Liao W.-Y.; Ho C.-C.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Jin-Shing Chen;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:46:16Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T02:50:36Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yang J.C.-H.; Yu C.-J.; Yao Z.-H.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C. |
| 臺大學術典藏 |
2020-08-12T06:34:19Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; CHONG-JEN YU; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Chong-Jen Yu |
| 臺大學術典藏 |
2019 |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; JIN-YUAN SHIH; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Jin-Yuan Shih;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yu C.-J.; Yang J.C.-H.; Lin C.-C.; Chen J.-S.; Lin Z.-Z. |
| 臺大學術典藏 |
2019 |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yu C.-J.; Yang J.C.-H.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Shih J.-Y.; Chen K.-Y.; Ho C.-C.; WEI-YU LIAO; Yao Z.-H.; Yao Z.-H.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T02:38:31Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Anonymous |
| 臺大學術典藏 |
2021-04-29T05:08:51Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Kuan-Yu Chen;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; Ho C.-C.; KUAN-YU CHEN; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-27T06:59:51Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020-05-25T07:35:05Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients
|
Yu C.-J.;Yang J.C.-H;Chia-Chi Lin;Lin Z.-Z;Chen J.-S;Shih J.-Y;Chen K.-Y;Ho C.-C;Liao W.-Y;Yao Z.-H; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Chia-Chi Lin; Yang J.C.-H; Yu C.-J. |
| 臺大學術典藏 |
2021-08-11T03:46:37Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-09T05:25:27Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients
|
ZONG-HAN YAO; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-10T06:10:57Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-26T07:52:27Z |
Incidence of hepatitis B virus infection in young Chinese blood donors born after mandatory implementation of neonatal hepatitis B vaccination nationwide
|
Tang X.;Allain J.-P.;Hurng-Yi Wang;Rong X.;Chen J.;Huang K.;Xu R.;Wang M.;Huang J.;Liao Q.;Shan Z.;Luo S.;Li T.;Li C.;Fu Y.; Tang X.; Allain J.-P.; HURNG-YI WANG; Rong X.; Chen J.; Huang K.; Xu R.; Wang M.; Huang J.; Liao Q.; Shan Z.; Luo S.; Li T.; Li C.; Fu Y. |
